Publications by authors named "Jacek C Szepietowski"

331 Publications

Body Shape Questionnaire-34 (BSQ) and Functionality Appreciation Scale (FAS) - pertinent body image screening tools: Creation and validation of Polish language versions.

Sci Prog 2022 Jul-Sep;105(3):368504221117068

Department of Dermatology, Venereology and Allergology, 49550Wroclaw Medical University, Wroclaw, Poland.

Objective: Body image is defined as the perception of one's own body. While positive body image has a positive impact on quality of life, self-dissatisfaction may lead to depression, anxiety and low self-esteem. Body image might be quantified and evaluated: relevant instruments include the Body Shape Questionnaire (BSQ) and the Functionality Appreciation Scale (FAS).This study was designed to translate and evaluate the psychometric properties of the Polish versions of these instruments.

Methods: Translation (both forward and backward) from the original English versions of the questionnaires met international standards. Internal consistency and test-retest reliability are reported from 89 participants for the BSQ and 103 for the FAS. The participants also completed the Polish versions of the Body Image Quality of Life Inventory (BIQLI) and the Body Appreciation Scale-2 (BAS-2) to explore convergent validity.

Results: Both, Polish versions of the BSQ and the FAS demonstrated good internal consistency and reproducibility. Convergent validity revealed a moderate relationship between the BSQ and the BIQLI scores, and a strong one between the FAS and the BAS-2 scores.

Conclusion: Polish versions of both BSQ and FAS questionnaires showed sufficiently strong psychometric properties to support their use in clinical and research work with Polish speaking patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/00368504221117068DOI Listing
August 2022

Prevention of Ageing-The Role of Micro-Needling in Neck and Cleavage Rejuvenation: A Narrative Review.

Int J Environ Res Public Health 2022 Jul 25;19(15). Epub 2022 Jul 25.

Department of Dermatology, Venereology and Allergology, Wrocław Medical University, 50-368 Wroclaw, Poland.

Although interest in aesthetic medicine is growing, the focus is often placed outside of the facial area, namely on the skin of the neck and cleavage. Exposure to the sun and muscle movements cause the prompt development of wrinkles that may appear there, even before they show up on the face. We conducted a literature review devoted to micro-needling to identify its role in anti-ageing treatments and to determine the gaps in current knowledge. A search in Medline identified 52 publications for neck and face micro-needling. Micro-needling is an anti-ageing procedure that involves making micro-punctures in the skin to induce skin remodelling by stimulating the fibroblasts responsible for collagen and elastin production. It can be applied to the skin of the face, neck, and cleavage. Two to four weeks should be allowed between repeated procedures to achieve an optimal effect. The increase in collagen and elastin in the skin can reach 400% after 6 months, with an increase in the thickness of the stratum granulosum occurring for up to 1 year. In conclusion, micro-needling can be considered an effective and safe aesthetic medicine procedure which is conducted at low costs due to its low invasiveness, low number of adverse reactions, and short recovery time. Little evidence identified in the literature suggests that this procedure requires further research.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph19159055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332435PMC
July 2022

High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients.

J Clin Med 2022 Jul 25;11(15). Epub 2022 Jul 25.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Chronic itch (CI) is a common symptom caused by both dermatological and systemic disorders. CI is also a frequent, burdensome symptom among renal transplant recipients (RTR); however, its pathophysiology is not fully understood. The aim of this study was to assess the differences in concentration of IL-31 among itchy RTR. The study was performed on a group of selected 129 RTRs (54 itchy and 75 non-itchy patients). Itch severity was assessed with the use of the numeral rating scale (NRS) and the 4-item itch questionnaire (4IIQ). Every subject had his blood drawn to measure the concentration of IL-31. The results were subsequently compared and correlated. The mean concentration differed significantly between RTR suffering from itch (602.44 ± 534.5 pg/mL), non-itchy RTR (161.49 ± 106.61 pg/mL), and HC (110.33 ± 51.81 pg/mL) ( < 0.001). Post-hoc analysis revealed a statistically significantly increased IL-31 serum concentration in itchy RTR in comparison to the non-itchy RTR group ( < 0.001) and HC ( < 0.001). No significant difference was observed in IL-31 serum levels between non-itchy RTRs and HC. No correlation between IL-31 and itch intensity was found. The results of our study clearly demonstrate the association between IL-31 levels and CI in patients after renal transplantation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm11154309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332266PMC
July 2022

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

J Am Acad Dermatol 2022 Jul 9. Epub 2022 Jul 9.

Oregon Medical Research Center, Portland, OR, USA.

Background: Effective, well-tolerated oral psoriasis treatments are needed.

Objective: To compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor (TYK2), versus placebo and apremilast in adults with moderate to severe plaque psoriasis.

Methods: Participants were randomized 2:1:1 to deucravacitinib 6 mg QD (n=332), placebo (n=166), or apremilast 30 mg BID (n=168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary endpoints included response rates for ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at Week 16.

Results: At Week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < 0.0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < 0.0001). Efficacy improved beyond Week 16 and was maintained through Week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.

Limitations: One-year duration, limited racial diversity.

Conclusion: Deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2022.07.002DOI Listing
July 2022

Dyed basal cell carcinoma: A peculiar clinical and histopathological case.

J Cosmet Dermatol 2022 Jul 11. Epub 2022 Jul 11.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocd.15229DOI Listing
July 2022

Itch in Hidradenitis Suppurativa/Acne Inversa: A Systematic Review.

J Clin Med 2022 Jun 30;11(13). Epub 2022 Jun 30.

Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany.

Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory disease of the pilosebaceous unit leading to formation of painful, inflammatory nodules, abscesses and tunnels in apocrine gland-bearing areas of the skin. Pain and drainage are the most important symptoms associated with reduction of quality of life in HS. On the other hand, an overlooked symptom in quality of life studies is itch, despite the fact that several studies have reported its importance. Various theories have tried to explain the pathogenesis of itch in HS, such as the presence of mast cells in the cell infiltrates and elevated Ig E levels in the lesional skin. Smoking and advanced stage of disease have been found to be associated with increased intensity of itch. A PUBMED search was conducted to perform a systematic literature review using the term "hidradenitis suppurativa" [all fields], the keywords "pruritus", "itching", "itch" [all fields] and with "AND" as operator. Mast cells and mTor signaling were found to be raised in both lesional and perilesional skin. Itch as a presenting symptom has been found in 35-82.6% of patients across multiple studies. It often co-presents with pain and may be misinterpreted as burning, stinging, tickling, tweaking, prickling, etc. The presence of itch is associated with reduced quality of life, depression and impairment of social life. Brodalumab, a monoclonal antibody against IL-17A receptor, produced significant improvements in itch, pain, QoL and depression in patients with moderate to severe HS. Statins have shown some reduction in itch intensity score. Further studies are required to gain a better understanding of the etiopathogenesis and optimal therapeutic modalities for itch in HS that will allow clinicians to better address issue and reduce its impact on quality of life.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm11133813DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267685PMC
June 2022

The Analysis of a Genome-Wide Association Study (GWAS) of Overweight and Obesity in Psoriasis.

Int J Mol Sci 2022 Jul 2;23(13). Epub 2022 Jul 2.

Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-210 Gdansk, Poland.

There is evidence that the concomitance of psoriasis and obesity may originate from the interplay between multiple genetic pathways and involve gene-gene interactions. The aim of this study was to compare the genetic background related to obesity among psoriatic patients versus healthy controls by means of a Genome-Wide Association Study (GWAS). A total of 972 psoriatic patients and a total of 5878 healthy donors were enrolled in this study. DNA samples were genotyped for over 500,000 single nucleotide polymorphisms (SNPs) using Infinium CoreExome BeadChips (Illumina, San Diego, CA, USA). Statistical analysis identified eleven signals ( < 1 × 10) associated with BMI across the study groups and revealed a varying effect size in each sub-cohort. Seven of the alternative alleles (rs1558902 in the gene, rs696574 in the gene, as well as rs10968110, rs4551082, rs4609724, rs9320269, and rs2338833,) are associated with increased BMI among all psoriatic patients and four (rs1556519 in the gene, rs12972098 in the gene, rs12676670 in the gene, and rs1321529) are associated with lower BMI. The results of our study may lead to further insights into the understanding of the pathogenesis of obesity among psoriatic patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms23137396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266424PMC
July 2022

Atopic Dermatitis: Sailing beyond the Sunset with a Multitude of Novel Treatments.

J Clin Med 2022 Jun 16;11(12). Epub 2022 Jun 16.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-367 Wroclaw, Poland.

Atopic eczema or dermatitis (AD) is a chronic pruritic inflammatory cutaneous disorder with an incidence up to 20% in children and 10% in adults depending on region and ethnicity [...].
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm11123475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225552PMC
June 2022

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.

Paediatr Drugs 2022 Jul 13;24(4):377-387. Epub 2022 Jun 13.

Novartis Pharma AG, Basel, Switzerland.

Background: The efficacy and safety of biologic treatments for children and adolescents with moderate to severe psoriasis should be examined over a considerable time period and in different subgroups.

Objective: We report the efficacy and safety of secukinumab low dose (LD) and high dose (HD) regimens in pediatric patients with moderate to severe psoriasis for up to Week 52.

Methods: This was a randomized, open-label, parallel-group, multicenter study in patients aged  6 to < 18 years. Patients were randomized in a 1:1 ratio to receive LD (75/75/150 mg; N = 42) or HD (75/150/300 mg; N = 42) subcutaneous secukinumab. At randomization, patients were stratified by weight (< 25, 25 to < 50, ≥ 50 kg) and disease severity (moderate/severe). The study is ongoing; the present analysis included data up to Week 52 collected from August 29, 2018 (first patient first visit) to May 28, 2020 (last patient last visit for Week 52). Efficacy was measured using Investigator's Global Assessment modified 2011 0/1 (IGA 0/1) and Psoriasis Area Severity Index (PASI) 75/90/100 response. Safety outcomes included assessment of adverse events.

Results: Of the 84 enrolled patients, 78 (92.9%) completed 52 weeks of treatment. Overall, response rates for PASI 75 and IGA 0/1 were similar between the LD (92.8/88.9%) and HD (93.3/84.7%) groups at Week 52. In the LD and HD groups, PASI 90/100 responses at Week 52 were 78.7/53.5% and 84.7/70.0%, respectively. The proportions of IGA 0/1 and PASI 75/90 responders were comparable for the age, body weight, and disease severity subgroups in the secukinumab LD and HD groups. Mean absolute PASI change from baseline at week 52 was - 17.3 ± standard deviation 5.0 and - 18.2 ± 7.0, a percentage change of - 94.3 and - 94.5% for the LD and HD groups, respectively. More than 70% of evaluable patients achieved Children's Dermatology Life Quality Index 0/1 at Week 52 (LD 70.7%; HD 70.3%). The safety profile was consistent with that in adults, with no new safety signals for either secukinumab dosing regimen.

Conclusion: A high proportion of pediatric patients with psoriasis responded to both dosing regimens of secukinumab and maintained clinical responses through 52 weeks of treatment. No clinical difference was observed in the efficacy of secukinumab across the pediatric subgroups. Safety events were consistent with the established safety profile of secukinumab.

Trial Registration: ClinicalTrials.gov: NCT03668613.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-022-00507-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205811PMC
July 2022

LAight® Therapy Is an Effective Treatment Option to Maintain Long-Term Remission of Hurley I and II Hidradenitis Suppurativa: Results from Period B of RELIEVE, a Multicenter Randomized, Controlled Trial.

Dermatology 2022 Jun 9:1-12. Epub 2022 Jun 9.

Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.

Background: Hidradenitis suppurativa is a chronic, inflammatory, burdensome skin disease where current first-line treatments are limited to topical and/or systemic antibiotics which cannot be applied for long-term disease management. Period B of the RELIEVE study analyzes whether LAight® therapy can sustain or even increase remission after a first topical antibiotic treatment cycle.

Methods: The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating Hurley I and II patients were randomized to either a group receiving topical clindamycin 1% solution combined with 8 additional bi-weekly treatments with LAight® therapy (group TC + L) or a group which was treated with topical clindamycin 1% solution only (group TC). After 16 weeks, patients entered open-label period B and both groups were treated exclusively with LAight® therapy for an additional 16 weeks (8 sessions, group TC + L/L and group TC/L).

Results: In total, 88 patients were enrolled in RELIEVE. Seventy-eight patients entered period B; 39 belonged to group TC + L/L and 39 to group TC/L. The IHS4-response at the start of period B was 62% (group TC + L/L) and 33% (group TC + L). During the 16 weeks of additional monotherapy with LAight, in both groups >90% of patients who responded to therapy in period A maintained their IHS4-response at week 32. IHS4 response rates continued to rise up to 79% of the TC + L/L group and up to 71% of the TC/L group during period B at week 32. Achievement of HiSCR and certain patient reported outcomes confirmed primary endpoint results.

Conclusion: LAight® therapy is an effective approved therapy option for Hurley I and II HS that can be used continuously to maintain treatment success. During 16 weeks of follow-up in period B, over 90% of patients with response after period A maintained their treatment outcome, while more than 60% of prior nonresponders gained response. The fact that LAight® therapy can be applied continuously, is very effective and is well tolerated makes it a valuable treatment tool in the design of HS long-term treatment modalities.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000524739DOI Listing
June 2022

Scrotum involvement in dermatomyositis.

Postepy Dermatol Alergol 2022 Apr 9;39(2):426-427. Epub 2022 May 9.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2020.99754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131959PMC
April 2022

Photoprotection among young children: assessment of mothers' awareness and health behaviours.

Postepy Dermatol Alergol 2022 Apr 26;39(2):392-396. Epub 2021 Oct 26.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw Poland.

Introduction: Due to the increasing incidence of skin cancer in the last decades a wide promotion of proper sun protection is needed. Mothers and their children commonly spending time outdoors are particularly vulnerable to the harmful effects of sunlight.

Aim: To assess health awareness and behaviours connected to sun protection in the group of mothers of children under 6 years of age.

Material And Methods: An online survey containing 23 questions (19 closed and 4 open) was carried out between July and August 2019. One hundred and seven women (mean age: 30.7 ±4.3years) participated in the study. The mean age of children was 1.9 ±1.6years (range: 0-6 years).

Results: One hundred and five (98.1%) mothers declared using sunscreen. Of them, 36 women used sunscreen only in summer, while 14 women applied sunscreen all year. Mothers of younger children used sunscreen all year round significantly more often ( = 0.041) compared to mothers of older children. Mothers of children under the age of 1 used sunscreen when staying in the shade more often ( = 0.025) than mothers of older children. Only 14 (13.3%) women declared applying sunscreen on their children during cloudy weather.

Conclusions: A good photoprotection awareness of mothers, especially with respect to the youngest children was observed. However, a need for further education regarding certain photoprotection aspects (proper application and damaging effect of UVA) is necessary.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2021.105820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131953PMC
April 2022

Psychosocial Burden of Itch among Renal Transplant Recipients.

Toxins (Basel) 2022 04 30;14(5). Epub 2022 Apr 30.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Itch is the most common symptom of chronic dermatoses. Moreover, itch may be associated with systemic disorders. Chronic kidney disease-associated itch (CKD-aI) may affect up to 20% of renal transplant recipients (RTR). The aim of the study was to assess psychosocial burden of itch in RTR. The study was performed on a group of 129 RTR, out of which 54 (41.9%) experienced itch in the previous 3 days. A specially designed questionnaire assessing anxiety, depression, stigmatization, and quality of life was used. Results: Patients suffering from itch in the previous 3 days achieved significantly higher scores in GAD-7 ( < 0.001), BDI ( < 0.001), HADS total score ( < 0.001), HADS Depression ( = 0.004), and HADS Anxiety ( < 0.001). Severity of itch correlated positively with HADS, stigmatization scale, and GAD-7. Itch in RTR was associated with higher incidence of depression assessed with BDI (OR 3.7). Moreover, higher prevalence of anxiety was found among patients suffering from CKD-aI, assessed with HADS A and GAD-7 (OR 2.7 and OR 4.8, respectively) The results of our study clearly demonstrate that itch among RTR is a significant burden. Higher prevalence of depression and anxiety in this groups indicate the necessity of addressing itch relief as a part of holistic approach to patients after renal transplantation.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins14050320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145006PMC
April 2022

Optical super-high magnification dermoscopy of pigmented and nonpigmented nodular basal cell carcinoma.

J Cosmet Dermatol 2022 May 14. Epub 2022 May 14.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocd.15082DOI Listing
May 2022

Surgical Treatment in Hidradenitis Suppurativa.

J Clin Med 2022 Apr 21;11(9). Epub 2022 Apr 21.

Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany.

Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory disorder of follicular occlusion with pubertal onset that presents as painful inflammatory nodules, sinus tracts, and tunnelling in apocrine-gland-rich areas, such as the axilla, groin, lower back, and buttocks. The disease course is complicated by contractures, keloids, and immobility and is often associated with a low quality of life. It is considered a disorder of follicular occlusion with secondary inflammation, though the exact cause is not known. Management can often be unsatisfactory and challenging due to the chronic nature of the disease and its adverse impact on the quality of life. A multidisciplinary approach is key to prompt optimal disease control. The early stages can be managed with medical treatment, but the advanced stages most likely require surgical intervention. Various surgical options are available, depending upon disease severity and patient preference. In this review an evidence-based outline of surgical options for the treatment of HS are discussed. Case reports, case series, cohort studies, case-control studies, and Randomized Clinical Trials (RCT)s available in medical databases regarding surgical options used in the treatment of HS were considered for the review presented in a narrative manner in this article.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm11092311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101712PMC
April 2022

Small-fibre Neuropathy in Patients with Type 2 Diabetes Mellitus and its Relationship with Diabetic Itch: Preliminary Results.

Acta Derm Venereol 2022 05 19;102:adv00719. Epub 2022 May 19.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chałubińskiego 1, PL-50-368 Wrocław, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2340/actadv.v102.933DOI Listing
May 2022

Safety evaluation of secukinumab in pediatric patients with plaque psoriasis.

Expert Opin Drug Saf 2022 Jun 2:1-6. Epub 2022 Jun 2.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wrocław, Poland.

Introduction: Psoriasis (Ps) is a common chronic, recurrent, immune-mediated, inflammatory skin disease affecting up to 2% of children. It has a well-established impact on patients' quality of life. Moreover, patients with psoriasis exhibit a higher prevalence of comorbidities, including hypertension, diabetes, and inflammatory bowel disease. Secukinumab is a fully human monoclonal IL-17A antibody, which has been approved for use in children with psoriasis. Nevertheless, there are very little data on the safety of this therapy in the pediatric population.

Areas Covered: The aim of this article was to perform an extensive review of available data concerning secukinumab safety and efficiency in the pediatric population used for the treatment of plaque psoriasis. Moreover, special attention was paid to underline the adverse effects of secukinumab.

Expert Opinion: Although there is very little evidence on the long-term safety of secukinumab use in the pediatric population, this therapy may be a promising modality in children with moderate to severe psoriasis. The available data confirm its favorable safety profile with no serious adverse events and unexpected events. Moreover, the clinical trials revealed sustained efficiency with respect to reaching PASI 75 and decreasing impact of the disease on quality of life.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2022.2073349DOI Listing
June 2022

Expression of MCM2 as a Proliferative Marker in Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.

In Vivo 2022 May-Jun;36(3):1245-1251

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland;

Background/aim: Minichromosome maintenance protein 2 (MCM2) can be considered an indicator of cancer clinical outcome. In this study, we tried to estimate the usefulness of assessing MCM2 protein expression in actinic keratosis (AK) and cutaneous squamous cell carcinoma (cSCC).

Materials And Methods: The study included 22 lesions of AK, 57 of cSCC and 17 tissue samples of the healthy skin.

Results: Higher average expression of MCM2 protein in cSCC and AK was demonstrated in comparison to healthy skin (p=0.01). Likewise, the level of MCM2 expression differed statistically significantly (p=0.02) between SCC, AK, and healthy skin. Significant correlations between MCM2 expression and Ki-67 and p53 antigen were found (r=0.51, p=0.01; r=0.45, p=0.04 respectively) in AK lesions, however these relationships were not noted in cSCC.

Conclusion: MCM2 is overexpressed in both AK and cSCC lesions, however this protein cannot be considered an important indicator of proliferation in cSCC.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.12823DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087098PMC
April 2022

The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?

Toxins (Basel) 2022 03 7;14(3). Epub 2022 Mar 7.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-31 (IL-31) to the pathogenesis of itch in patients undergoing maintenance hemodialysis (HD). We evaluated the serum level of IL-31 in HD patients with pruritus, in HD patients without pruritus and in healthy controls, as well as its correlation to the severity of itch. The study enrolled 175 adult subjects. The participants were divided into three groups. Group A included 64 patients on maintenance HD with CKD-aP, Group B included 62 patients on maintenance HD not reporting CKD-aP and Group C included 49 healthy controls. Pruritus severity was assessed using the Numerical Rating Scale (NRS), and the serum levels of IL-31 were measured. The results showed that the IL-31 serum level was significantly higher in the itchy group ( < 0.001) in comparison to the patients free from pruritus. Moreover, a marginal trend towards significance (r = 0.242, = 0.058) was observed between the IL-31 serum level and itch intensity. Our study supports earlier findings on the extended role of IL-31 in the development of CKD-aP.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins14030197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955714PMC
March 2022

Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice?

Dermatol Ther (Heidelb) 2022 Apr 10;12(4):899-909. Epub 2022 Mar 10.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chalubinskiego Street 1, 50-368, Wrocław, Poland.

Introduction: Hidradenitis suppurativa (HS) is considered to be the most burdensome dermatosis, with a well-documented negative influence on quality of life (QoL). The patient's perception of the disorder, assessed as the self-reported severity, has been used in other dermatoses but not in HS. The aim of this study was to evaluate the usefulness of self-reported HS severity in clinical practice.

Methods: The study was performed on a group of 130 Spanish HS patients. HS severity was assessed for all the subjects. Hurley staging and patient self-reported severity were used. Moreover, QoL impairment was evaluated using the Dermatology Life Quality Index (DLQI) and the Hidradenitis Suppurativa Quality of Life 24 (HSQoL-24) questionnaire.

Results: The severity of HS according to the Hurley staging was most commonly assessed as Hurley II (47.7%), indicating moderate disease, followed by severe disease (Hurley III, 26.9%) and mild disease (Hurley I, 25.4%). According to the patient self-reported HS severity, most of the patients reported having mild disease (76 patients, 58.5%), followed by moderate disease (31 patients, 23.8%). Only 23 patients (17.7%) assessed their disease as severe. Moreover, men reported mild disease significantly more frequently than women (70.9% and 49.3%, respectively; p = 0.014). The self-reported HS severity correlated positively with the effect of the disease on patient QoL assessed with DLQI (r = 0.288, p < 0.001). Likewise, a strong positive correlation was found between self-reported HS severity and QoL impairment assessed with HSQoL-24 (r = 0.404, p = 0.001). No statistically significant correlation between Hurley severity stage and DLQI or HSQoL-24 was found. Moreover, there were significant differences in both DLQI and HSQoL-24 total score between different self-reported HS severities. This was not seen for any of the QoL instruments or for Hurley severity staging.

Conclusion: The results show that self-assessment severity may reflect patients' subjective feelings more adequately than popular objective instruments, and there should be a place for its use in daily clinical practice.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-022-00701-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021336PMC
April 2022

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life.

J Clin Med 2022 Feb 25;11(5). Epub 2022 Feb 25.

Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-210 Gdansk, Poland.

The epidemiology of psoriasis has not been widely assessed in Polish population so far. This study aimed to investigate psoriasis epidemiological situation by evaluating disease course and severity, management, comorbidities, environmental factors, and knowledge about this disorder among psoriatic patients in Poland. A cross-sectional cohort population-based study enrolled 1080 psoriatic patients and 1200 controls. The mean age of psoriasis onset was 27.6 years; 78.24% had type I psoriasis. Positive family history of psoriasis was reported in 44.81% of patients, whereas itch was reported in vast majority of patients (83.33%). Based on PASI score moderate psoriasis was the most common in studied group (mean 12.63 ± 9.33, range 0-67.2). The DLQI score (12.01 ± 7.41, range 0-30.0) indicated a very large effect of psoriasis on the quality of life. Hypertension was the most prevalent comorbidity (33.80%), followed by obesity (16.85%) and dyslipidemia (11.85%). Stress was the foremost cause of disease exacerbation (66.20%); however, infections (44.07%) and seasonal changes (45.09%) had also an impact on the course of psoriasis. Psoriatic patients were more often smokers (37.59%) vs. general population (27.50%; < 0.0001). In conclusion, epidemiological studies help clinicians in better disease and patient understanding, which may translate into better management and patient compliance.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm11051254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911198PMC
February 2022

Sudden Onset of Unilateral Facial Paralysis with Ear Pruritus: A Quiz.

Acta Derm Venereol 2022 Mar 22;102:adv00675. Epub 2022 Mar 22.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, ul. Chałubińskiego 1, PL-50-368 Wrocław, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2340/actadv.v102.756DOI Listing
March 2022

Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management.

Int J Dermatol 2022 Feb 22. Epub 2022 Feb 22.

Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma. However, it is rare in pediatric population. Most of the cases of pediatric MF present with hypopigmented patches and/or various other forms, which may often mimic common childhood dermatoses, thereby causing a delay in the diagnosis. There are no established treatment guidelines for pediatric MF. As the progression of childhood MF is extremely rare and it has an indolent course, it is usually diagnosed at an early stage (IA, IB, IIA), and hence phototherapy with a response rate of >80% is a well-established effective treatment in children. However, as recurrences are frequently seen on stopping the therapies, a maintenance regimen and long-term follow-up is equally important. This article reviews the epidemiological factors, clinical presentations, diagnosis, and various treatment modalities used in pediatric MF. We analyzed and compared the data of almost 616 childhood MF cases from various studies undertaken from 1988 to 2021.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.16098DOI Listing
February 2022

Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa.

J Clin Med 2022 Jan 27;11(3). Epub 2022 Jan 27.

Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany.

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of the apocrine glands characterized by recurrent episodes. Although several therapies exist, none is completely curative. Several immunosuppressives have been studied with encouraging results and targeted approaches. In this review, we highlight the various immunosuppressives used in this condition along with their salient features to enable physicians to choose the correct therapy for their patients. The search of the peer-reviewed literature included clinical trials, scientific reviews, case series, case reports, and guidelines. The literature was identified from electronic databases (MEDLINE and PubMed) through November 2021; additional articles were included from the references of the identified articles.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm11030670DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836901PMC
January 2022

Wiederkehrende spontane Petechien und Ekchymosen bei einem 14-jährigen Mädchen.

J Dtsch Dermatol Ges 2022 Feb;20(2):227-230

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.14686_gDOI Listing
February 2022

Basal Cell Carcinoma Arising within a Bacillus Calmette-Guerin Scar: Case Report and Literature Review.

Acta Derm Venereol 2022 Feb 28;102:adv00657. Epub 2022 Feb 28.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2340/actadv.v102.328DOI Listing
February 2022

Basal cell carcinoma: what new can be learned about the most common human cancer? A cross-sectional prospective study of 180 cases in a single centre.

Postepy Dermatol Alergol 2021 Dec 22;38(6):1086-1091. Epub 2021 Oct 22.

Department of Dermatology, Venereology, and Allergology, Wroclaw Medical University, Wroclaw, Poland.

Introduction: Basal cell carcinoma (BCC) is the most common cancer in humans, but the reporting of patients with BCC is still not complete. There are a limited number of analyses in the literature on BCC epidemiology.

Aim: To study the epidemiological as well as clinical aspects of BCC by analysing a single centre's experience in the Lower Silesia region of Poland.

Material And Methods: We investigated 180 patients with BCC treated in the Unit of Dermatosurgery, Department of Dermatology, Venereology, and Allergology of Wroclaw Medical University between September 2017 and December 2019.

Results: The mean age of patients with BCC was 70.5 ±11.9 years. The most frequently diagnosed type of BCC was nodular type, at 72% of all patients. BCC occurred most commonly on the face and neck area, at 132 (73.3%), without a statistical difference between males and females. The vast majority of cancers were located on the nose. There was a personal history of skin cancer in 29% of our patients. In 127 (70.6%) subjects, the diameter of the BCC on the day of excision was less than 2 cm.

Conclusions: The clinical characteristics of our cohort of BCC patients has some similarities with that reported from central Poland and other European countries. However, we found an increase in the incidence of BCC among females.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2021.106026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802970PMC
December 2021

Comparison of serum concentrations of interleukins 10, 12, 17 and 35 between patients with alopecia areata and controls.

Postepy Dermatol Alergol 2021 Dec 7;38(6):1052-1057. Epub 2022 Jan 7.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

Introduction: Alopecia areata (AA) is one of the most common causes of non-scarring hair loss in adults and children with unknown etiopathogenesis, however immunological factors play an important role.

Aim: To evaluate the concentration of interleukin (IL) 10 (IL-10), IL-12, IL-17 and IL-35 in the blood serum of patients with AA.

Material And Methods: AA study group consisted of 118 patients. The control group consisted of 54 healthy individuals. The severity of the disease was assessed by SALT score. In the study group, the percentage of hair loss averaged 49.6% ±36.3%. The concentration of IL-10, IL-12, IL-17 and IL-35 in the serum was assessed by the enzyme-linked immunosorbent assays (ELISA).

Results: In patients with AA, the level of IL-12 and IL-17 was significantly higher than in the control group ( > 0.05). The level of IL-10 in patients was slightly higher, whereas the level of IL-35 was slightly lower, compared to the control group, but those differences were not statistically significant. Furthermore, in patients with more severe disease the IL-12 level was significantly higher as compared to patients with the less severe AA ( < 0.05).

Conclusions: The etiopathogenesis of AA is complex, however Th1 and Th17 lymphocytes and their increased activity are undoubtedly significant contributors in this process. Disorders of immunological processes in AA require further research in order to understand the underlying pathomechanisms of the disease and to provide potential therapeutic strategies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2021.112278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802955PMC
December 2021

Hidradenitis Suppurativa Quality of Life (HiSQOL): creation and validation of the Polish language version.

Postepy Dermatol Alergol 2021 Dec 14;38(6):967-972. Epub 2020 Jul 14.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory and painful cutaneous disease which often has a negative influence on patients' quality of life. Dermatology-specific instruments, such as Dermatology Life Quality Index and Skindex, are commonly used to evaluate HS patients' quality of life. However, due to the lack of specific questions, these scales may not be adequate and may not reflect the real problem.

Aim: To translate and validate the Polish version of a newly created HS-specific questionnaire - Hidradenitis Suppurativa Quality of Life (HiSQOL).

Material And Methods: A forward and backward translation was conducted from the original English version of the questionnaire to Polish language according to international standards. The validation was performed on a group of 30 patients suffering from HS, who completed the questionnaire twice with a 4-5 days' interval.

Results: The Polish version of HiSQOL questionnaire showed a very good internal consistency (Cronbach α coefficient was 0.96 for total score). Excellent reproducibility with the intraclass correlation coefficient (ICC) of 0.97 was demonstrated.

Conclusions: The Polish version of HiSQOL questionnaire has high internal reliability, validity and reproducibility. It can be used as a tool to assess health-related quality of life in the patients suffering from hidradenitis suppurativa.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2020.97064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802972PMC
December 2021
-->